Skip to main content Accessibility help
×
Home
Hostname: page-component-59b7f5684b-7j4dq Total loading time: 0.285 Render date: 2022-10-01T21:27:02.739Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": false, "useSa": true } hasContentIssue true

Author reply

Published online by Cambridge University Press:  18 July 2022

Joanna Moncrieff
Affiliation:
Professor of Critical and Social Psychiatry, University College London, UK
Mark Horowitz
Affiliation:
Clinical Research Fellow, University College London, UK. Email: j.moncrieff@ucl.ac.uk

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Carhart-Harris, R, Giribaldi, B, Watts, R, Baker-Jones, M, Murphy-Beiner, A, Murphy, R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–11.CrossRefGoogle ScholarPubMed
Chen, JA, Papakostas, GI, Youn, SJ, Baer, L, Clain, AJ, Fava, M, et al. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry 2011; 72: 1669–76.CrossRefGoogle ScholarPubMed
Popova, V, Daly, EJ, Trivedi, M, Cooper, K, Lane, R, Lim, P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019; 176: 428–38.CrossRefGoogle ScholarPubMed
Baudot, J, Soeiro, T, Tambon, M, Navarro, N, Veyrac, G, Mezaache, S, et al. Safety concerns on the abuse potential of esketamine: multidimensional analysis of a new anti-depressive drug on the market. Fundam Clin Pharmacol [Epub ahead of print] 15 Dec 2021. Available from: https://doi.org/10.1111/fcp.12745.CrossRefGoogle Scholar
Taillefer de Laportalière, T, Yrondi, A, Jullien, A, Cestac, P, Montastruc, F. How to deprescribe esketamine in resistant depression? A point of view after first clinical uses. Epidemiol Psychiatr Sci 2022; 31: e4.CrossRefGoogle ScholarPubMed
Castellani, D, Pirola, GM, Gubbiotti, M, Rubilotta, E, Gudaru, K, Gregori, A, et al. What urologists need to know about ketamine-induced uropathy: a systematic review. Neurourol Urodyn 2020; 39: 1049–62.CrossRefGoogle ScholarPubMed
Horowitz, MA, Moncrieff, J. Are we repeating mistakes of the past? A review of the evidence for esketamine. Br J Psychiatry 2021; 219(5): 614–7.CrossRefGoogle Scholar
Gastaldon, C, Raschi, E, Kane, JM, Barbui, C, Schoretsanitis, G. Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom 2021; 90(1): 41–8.CrossRefGoogle Scholar
Osgood, K. Big tech's psychedelics grift. Wired, Nov 7 2021. Available from: https://www.wired.com/story/psychedelics-psychiatry-big-tech-mental-health/ [cited 30 Jan 2022].Google Scholar
Thielking, M. Is the ketamine boom getting out of hand? Scientific American, 26 Sep 2018. Available from: https://www.scientificamerican.com/article/is-the-ketamine-boom-getting-out-of-hand/ [cited 30 Jan 2022].Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Author reply
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Author reply
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Author reply
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *